http://ift.tt/2niMpIe
“The revenue and profit growth for the company during the financial year was driven primarily due to the sales of generic Oseltamivir product in the USA market and continued growth of domestic formulations business,” Natco said in a statement.
May 30, 2017 at 05:06PM
from
No comments:
Post a Comment